These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33212064)

  • 21. Severe Polyneuropathy in Hereditary Transthyretin Amyloidosis Caused by H90D Variant.
    Pierce J; Han K; Vinters HV; Zuckerman JE; Halabi A
    Can J Neurol Sci; 2024 Mar; 51(2):336-338. PubMed ID: 36624082
    [No Abstract]   [Full Text] [Related]  

  • 22. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
    J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [de novo hATTR amyloidosis after domino transplantation of a donor's liver: a case report for the use of Patisiran].
    Schmidt M; Yilmaz A; Bietenbeck M; Schilling M; Röcken C; Schmidt HH
    Z Gastroenterol; 2022 Nov; 60(11):1659-1664. PubMed ID: 35533685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Gorevic P; Franklin J; Chen J; Sajeev G; Wang JCH; Lin H
    Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transthyretin deposition in familial amyloidotic polyneuropathy.
    Saraiva MJ; Magalhaes J; Ferreira N; Almeida MR
    Curr Med Chem; 2012; 19(15):2304-11. PubMed ID: 22471982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patisiran in Patients with Transthyretin Cardiac Amyloidosis.
    Martínez-Sellés M
    N Engl J Med; 2024 Jan; 390(3):286. PubMed ID: 38231632
    [No Abstract]   [Full Text] [Related]  

  • 27. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
    Coelho T; Adams D; Conceição I; Waddington-Cruz M; Schmidt HH; Buades J; Campistol J; Berk JL; Polydefkis M; Wang JJ; Chen J; Sweetser MT; Gollob J; Suhr OB
    Orphanet J Rare Dis; 2020 Jul; 15(1):179. PubMed ID: 32641071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patisiran in Patients with Transthyretin Cardiac Amyloidosis. Reply.
    Maurer MS; Gillmore JD
    N Engl J Med; 2024 Jan; 390(3):286-287. PubMed ID: 38231633
    [No Abstract]   [Full Text] [Related]  

  • 29. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transthyretin amyloidosis: a little history of hereditary amyloidosis.
    Benson MD
    Amyloid; 2017 Mar; 24(sup1):76-77. PubMed ID: 28434305
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
    Ticau S; Aldinc E; Polydefkis M; Adams D; Coelho T; Ueda M; Hale C; Vest J; Nioi P;
    Amyloid; 2024 Mar; 31(1):1-11. PubMed ID: 37469249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
    Kristen AV; Ajroud-Driss S; Conceição I; Gorevic P; Kyriakides T; Obici L
    Neurodegener Dis Manag; 2019 Feb; 9(1):5-23. PubMed ID: 30480471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary amyloid neuropathy by transthyretin Val107 mutation in a patient of African origin.
    Cassereau J; Lavigne C; Letournel F; Ghali A; Verny C; Dubas F; Devière F; Nicolas G
    J Peripher Nerv Syst; 2008 Sep; 13(3):251-4. PubMed ID: 18844793
    [No Abstract]   [Full Text] [Related]  

  • 34. From a misdiagnosis of anorexia nervosa to a dramatic patisiran-induced improvement in a patient with ATTRE89Q amyloidosis.
    Russo M; Gentile L; Toscano A; Vita G; Mazzeo A
    Amyloid; 2020 Dec; 27(4):279-280. PubMed ID: 32515606
    [No Abstract]   [Full Text] [Related]  

  • 35. Two cases of late onset familial amyloid polyneuropathy with a Glu61Lys transthyretin variant.
    Nakano Y; Tadokoro K; Ohta Y; Sato K; Takemoto M; Hishikawa N; Yamashita T; Yamashita T; Ando Y; Abe K
    J Neurol Sci; 2018 Jul; 390():22-25. PubMed ID: 29801893
    [No Abstract]   [Full Text] [Related]  

  • 36. siRNA therapy improves multimodality imaging in hereditary transthyretin cardiac amyloidosis: a case report.
    Awaya T; Endo J; Iijima R; Shimoda M; Moroi M
    QJM; 2024 Apr; 117(4):304-306. PubMed ID: 38229248
    [No Abstract]   [Full Text] [Related]  

  • 37. APOE polymorphism in ATTR amyloidosis patients treated with lipid nanoparticle siRNA.
    Niemietz C; Nadzemova O; Zibert A; Schmidt HH
    Amyloid; 2020 Mar; 27(1):45-51. PubMed ID: 31648569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis.
    Lau KHV; Prokaeva T; Zheng L; Doros G; Kaku MC; Spencer B; Berk J; Sanchorawala V
    Amyloid; 2024 Jun; 31(2):150-152. PubMed ID: 38073425
    [No Abstract]   [Full Text] [Related]  

  • 39. [What gnaws at the heart and gets on the nerves].
    Kristen AV
    Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [ATTRv amyloidosis with early improvement demonstrated by the 6-minute walk test following Patisiran therapy: a case report].
    Oginezawa S; Ishihara T; Iwafuchi Y; Hatano Y; Kashimura K; Onodera O
    Rinsho Shinkeigaku; 2022 May; 62(5):375-379. PubMed ID: 35474286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.